PSORCON E Drug Patent Profile

When do Psorcon E patents expire, and when can generic versions of Psorcon E launch?

Psorcon E is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in PSORCON E is diflorasone diacetate. There are three drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the diflorasone diacetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Psorcon E

A generic version of PSORCON E was approved as diflorasone diacetate by AVONDALE PHARMS on April 27^th, 1999.

Summary for PSORCON E

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	59
Patent Applications:	6,039
DailyMed Link:	PSORCON E at DailyMed

US Patents and Regulatory Information for PSORCON E

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	PSORCON E	diflorasone diacetate	OINTMENT;TOPICAL	017994-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for PSORCON E

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	PSORCON E	diflorasone diacetate	OINTMENT;TOPICAL	017994-001	Approved Prior to Jan 1, 1982

International Patents for PSORCON E

See the table below for patents covering PSORCON E around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	2365992
Belgium	796560
France	2181802
Netherlands	7303262

PSORCON E Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for PSORCON E (Diflorasone Diacetate)

Introduction

PSORCON E, containing the active ingredient diflorasone diacetate, is a high-potency topical corticosteroid used for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Here, we will delve into the market dynamics and financial trajectory of this drug.

Market Overview

The market for topical corticosteroids is significant, driven by the prevalence of skin conditions such as psoriasis, atopic dermatitis, and other corticosteroid-responsive dermatoses. PSORCON E, with its high potency, is positioned to address these conditions effectively.

Product Availability and Discontinuation

The PSORCON brand name has been discontinued in the U.S., but generic versions of diflorasone diacetate may still be available, approved by the FDA[1].

Competitive Landscape

The market for topical corticosteroids is competitive, with various products available from different manufacturers. Companies like Taro Pharmaceuticals and Teligent, Inc. play significant roles in the generic and branded generic pharmaceutical markets, including topical products[1][3].

Sales and Revenue

While specific sales data for PSORCON E alone is not readily available due to its discontinuation, the broader market for topical corticosteroids is substantial. For instance, companies like Sanofi, which operate in the biopharma sector, report significant sales growth in their dermatology segments, although these figures are not directly attributed to PSORCON E[2].

Generic Market Impact

The availability of generic versions of diflorasone diacetate can significantly impact the financial trajectory of the drug. Generic products often reduce the market share and revenue of the original branded product, as they offer a more affordable alternative. Companies like Teligent, Inc. focus on developing and marketing generic topical pharmaceutical products, which can affect the pricing and market dynamics of branded products like PSORCON E[3].

Regulatory Environment

The regulatory environment plays a crucial role in the market dynamics of pharmaceutical products. FDA approvals and compliance with regulatory standards are essential for the continued availability of generic versions of diflorasone diacetate. Any changes in regulatory requirements or approvals can impact the financial trajectory of these products[1][3].

Patient and Prescriber Preferences

Patient and prescriber preferences also influence the market dynamics. High-potency corticosteroids like PSORCON E are often prescribed for severe skin conditions, but their use must be balanced against potential side effects such as adrenal suppression and Cushing's syndrome. This balance can affect prescribing patterns and patient adherence, impacting sales and revenue[1].

Financial Performance of Related Companies

Companies involved in the production and distribution of topical corticosteroids, such as Taro Pharmaceuticals and Teligent, Inc., provide insights into the financial performance of this market segment. For example, Teligent, Inc. has experienced fluctuations in revenue due to various factors, including the COVID-19 pandemic and liquidity issues. However, their focus on expanding their generic topical product portfolio indicates a potential for growth in this segment[3].

Future Outlook

The future outlook for PSORCON E and similar topical corticosteroids depends on several factors:

• Generic Competition: The presence of generic versions will continue to influence pricing and market share.
• Regulatory Changes: Any changes in FDA regulations or approvals can impact the availability and sales of these products.
• Market Demand: The ongoing demand for effective treatments for skin conditions will drive the market for topical corticosteroids.
• Innovation: Advances in dermatology treatments, including biologic medicines, may shift market dynamics and patient preferences[1][2][3].

Key Takeaways

• PSORCON E, though discontinued under its brand name, remains available in generic forms.
• The market for topical corticosteroids is competitive and influenced by generic competition.
• Regulatory compliance and patient/prescriber preferences are crucial factors.
• Companies involved in this market segment face various financial challenges and opportunities.

FAQs

What is PSORCON E used for?

PSORCON E (diflorasone diacetate) is used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses[1].

Why was the PSORCON brand name discontinued?

The PSORCON brand name has been discontinued in the U.S., but generic versions of the product may still be available[1].

What are the potential side effects of PSORCON E?

Potential side effects include adrenal suppression, Cushing's syndrome, and intracranial hypertension, especially in pediatric patients[1].

Can PSORCON E be used during pregnancy?

PSORCON E should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, as there are no adequate and well-controlled studies on its teratogenic potential[1].

Is PSORCON E safe for pediatric use?

The safety and effectiveness of PSORCON E in pediatric patients have not been established, and pediatric patients are at a greater risk of HPA-axis suppression and other adverse effects[1].

Cited Sources

1. Drugs.com - Psorcon: Package Insert / Prescribing Information
2. Sanofi - Q2 2024 Financial Report
3. Teligent, Inc. - Annual Report on Form 10-K for 2020